Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment
Gaceta Médica de México · 2025
DOI: 10.24875/gmm.24000311 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Gaceta Médica de México, 2025. Verfasst von Galnares-Olalde A Javier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromuscular Deseases, Instituto Nacional de Neurología y Neurocirugía, México City, Mexico. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, Immunoglobulins, Intravenous, Immunoglobulin G, Immunologic Factors.
Abstract (Originalsprache)
BACKGROUND: Guillain-Barré syndrome (GBS) is associated with 20% rate of long-term disability. This study explores the pathophysiology of GBS and the mechanism of intravenous immunoglobulin (IVIg). OBJECTIVE: To investigate whether elevated immunoglobulin G (IgG) levels following IVIg administration are linked to improved recovery of independent walking at 6 months. MATERIAL AND METHODS: A retro-prospective observational study was conducted. IgG levels were measured before treatment, 7- and 30-days post-initiation. Binary regression analysis assessed the impact of individual factors on prognosis and sequelae. The Kaplan-Meier curve was used to evaluate the proportion of patients who couldn´t walk unaided. RESULTS: Forty-two patients were included. The mean baseline IgG level was 832.25 mg/dl, increasing to 3053.48 mg/dl at 7 days and decreasing to 1091.72 mg/dl at 30 days. IgG increases at 7 days were categorized into quartiles. Patients with a low increase in IgG levels (< 1945.5 mg/dl) at 7 days exhibited more severe clinical manifestations, including greater needs for invasive mechanical ventilation and increased autonomic dysfunction. Also had poorer walking outcomes at 6 months. CONCLUSIONS: Lower increase in IgG levels at 7 days post-treatment is associated with a worse prognosis at 6 months, including a reduced likelihood of walking unaided. ANTECEDENTES: El síndrome de Guillain-Barré (SGB) se asocia a una frecuencia de 20 % de discapacidad a largo plazo. Este estudio examina la fisiopatología del SGB y el papel de la inmunoglobulina (Ig) intravenosa. OBJETIVO: Investigar si niveles elevados de inmunoglobulina G (IgG) tras la administración de Ig intravenosa están relacionados con mejor recuperación de la marcha independiente a los seis meses. MATERIAL y MÉTODOS: Estudio observacional retroprospectivo de 42 pacientes. Los niveles de IgG se midieron antes del tratamiento y a los siete y 30 días postratamiento. Se empleó regresión binaria para analizar el impacto de factores individuales en el pronóstico y las secuelas. La curva de Kaplan-Meier evaluó la proporción de pacientes incapaces de caminar sin ayuda. RESULTADOS: El nivel medio basal de IgG fue de 832.25 mg/dL, que se incrementó a 3053.48 mg/dL al día 7 y disminuyó a 1091.72 mg/dL al día 30 postratamiento. Los pacientes con incremento < 1945.5 mg/dL de IgG mostraron manifestaciones clínicas más graves, mayor necesidad de ventilación mecánica invasiva, disfunción autonómica y peores resultados en la marcha a los seis meses. CONCLUSIONES: El menor incremento de los niveles de IgG al día 7 postratamiento se asoció a peor pronóstico a los seis meses y menor probabilidad de marcha independiente.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuromuscular Deseases, Instituto Nacional de Neurología y Neurocirugía, México City, Mexico.
Zitieren
APA
Javier, G. A., Juan, L. C., Verónica, D. T., & Edwin, V. S. (2025). Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment. Gaceta Médica de México. https://doi.org/10.24875/gmm.24000311
Vancouver
Javier GA, Juan LC, Verónica DT, Edwin VS. Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment. Gaceta Médica de México. 2025. doi:10.24875/gmm.24000311
BibTeX
@article{Javier2025,
author = {Javier, Galnares-Olalde A and Juan, López-Hernández C and Verónica, Domínguez-Tobón and Edwin, Vargas-Cañas S},
title = {Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment},
journal = {Gaceta Médica de México},
year = {2025},
doi = {10.24875/gmm.24000311}
}
EUVIMED